Angela Lukin, Pfizer executive, said Pfizer Inc. is expected to roughly quadruple the price of the COVID-19 vaccine hike to about $110 to $130 per dose after the current purchase program by the U.S. government expires
Weak demand for Covid-19 vaccine at this current situation pushes the vaccine maker to hike prices to meet revenue forecasts in 2023 and beyond.
The firm expected the markets to move to private insurance after the U.S. public health emergency expires. The U.S. government is now paying around $30 per dose to Pfizer and BioNTech SE.
In the U.S., around 14.8 million people received a booster shot over the first week of the roll out. And within the first six weeks of the 2021 revaccination campaign, over 22 million people received the third shot.
“We are confident that the U.S. price point of the Covid-19 vaccine reflects its overall cost effectiveness and ensures the price will not be a barrier for access for patients,” Lukin said,
